Literature DB >> 23229099

Overexpression of MAC30 is associated with poor clinical outcome in human non-small-cell lung cancer.

Kai-Yu Han1, Xin Gu, Hao-Ran Wang, Dong Liu, Fu-Zhen Lv, Jia-Ning Li.   

Abstract

The aim of this study was to detect MAC30 expression in human non-small cell lung cancer (NSCLC) and to analyze its association with prognosis of NSCLC patients. Quantitative real-time RT-PCR was performed to examine the expression of MAC30 mRNA in 20 cases of NSCLC and corresponding non-tumor tissue samples. Immunohistochemistry was performed to detect the expression of MAC30 in 95 NSCLC tissues. We found that the expression levels of MAC30 mRNA in NSCLC tissues were significantly higher than those in corresponding non-tumor tissues. High-level MAC30 expression was correlated with poor tumor differentiation, TNM stage, and lymph node metastasis. Patients with high expression levels of MAC30 showed lower overall survival rate than those with low expression levels. Multivariate analysis showed that high MAC30 protein expression was an independent prognostic factor for NSCLC patients. Our study suggests that over-expression of MAC30 may play an important role in the progression of NSCLC and MAC30 expression may offer a valuable marker for predicting the outcome of patients with NSCLC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23229099     DOI: 10.1007/s13277-012-0612-z

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  15 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

Review 2.  Non-Hodgkin lymphoma: an update.

Authors:  Bryan T Hennessy; Emer O Hanrahan; Peter A Daly
Journal:  Lancet Oncol       Date:  2004-06       Impact factor: 41.316

3.  Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial.

Authors:  K Kelly; J Crowley; P A Bunn; C A Presant; P K Grevstad; C M Moinpour; S D Ramsey; A J Wozniak; G R Weiss; D F Moore; V K Israel; R B Livingston; D R Gandara
Journal:  J Clin Oncol       Date:  2001-07-01       Impact factor: 44.544

4.  TNM Classification of Malignant Tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer.

Authors:  L H Sobin; I D Fleming
Journal:  Cancer       Date:  1997-11-01       Impact factor: 6.860

5.  Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world.

Authors:  Farin Kamangar; Graça M Dores; William F Anderson
Journal:  J Clin Oncol       Date:  2006-05-10       Impact factor: 44.544

6.  Targets of c-Jun NH(2)-terminal kinase 2-mediated tumor growth regulation revealed by serial analysis of gene expression.

Authors:  Olga Potapova; Sergey V Anisimov; Myriam Gorospe; Ryan H Dougherty; William A Gaarde; Kenneth R Boheler; Nikki J Holbrook
Journal:  Cancer Res       Date:  2002-06-01       Impact factor: 12.701

7.  Significance of mRNA and protein expression of MAC30 in progression of colorectal cancer.

Authors:  Zeng-Ren Zhao; Li-Jing Zhang; Xin-Qi He; Zhi-Yong Zhang; Feng Zhang; Fang Li; Yong-Bin Pei; Yue-Ming Hu; Ming-Wei Wang; Xiao-Feng Sun
Journal:  Chemotherapy       Date:  2011-10-18       Impact factor: 2.544

8.  Identification and characterization of genes differentially expressed in meningiomas.

Authors:  M Murphy; M J Pykett; P Harnish; K D Zang; D L George
Journal:  Cell Growth Differ       Date:  1993-09

9.  Expression analysis of MAC30 in human pancreatic cancer and tumors of the gastrointestinal tract.

Authors:  H Kayed; J Kleeff; J Ding; J Hammer; T Giese; H Zentgraf; M W Büchler; H Friess
Journal:  Histol Histopathol       Date:  2004-10       Impact factor: 2.303

10.  Expression of MAC30 in rectal cancers with or without preoperative radiotherapy.

Authors:  Zhi-Yong Zhang; Zeng-Ren Zhao; Gunnar Adell; Ingvar Jarlsfelt; Yong-Xing Cui; Hany Kayed; Jorg Kleeff; Ming-Wei Wang; Xiao-Feng Sun
Journal:  Oncology       Date:  2007-07-26       Impact factor: 2.935

View more
  11 in total

1.  RNA interference against TMEM97 inhibits cell proliferation, migration, and invasion in glioma cells.

Authors:  Guanzhong Qiu; Wei Sun; Yongxiang Zou; Zheng Cai; Peng Wang; Xianbin Lin; Jinxiang Huang; Lei Jiang; Xuehua Ding; Guohan Hu
Journal:  Tumour Biol       Date:  2015-05-23

2.  Synthesis, Cytotoxicity Evaluation, and Computational Insights of Novel 1,4-Diazepane-Based Sigma Ligands.

Authors:  Daniele Zampieri; Sara Fortuna; Antonella Calabretti; Maurizio Romano; Renzo Menegazzi; Dirk Schepmann; Bernhard Wünsch; Maria Grazia Mamolo
Journal:  ACS Med Chem Lett       Date:  2019-12-16       Impact factor: 4.345

3.  EGFR mutation status and its impact on survival of Chinese non-small cell lung cancer patients with brain metastases.

Authors:  Dongdong Luo; Xin Ye; Zheng Hu; Kaiwen Peng; Ye Song; Xiaolu Yin; Guanshan Zhu; Qunsheng Ji; Yuping Peng
Journal:  Tumour Biol       Date:  2013-11-07

4.  The Prognostic Effect of MAC30 Expression on Patients With Non-Small Cell Lung Cancer Receiving Adjuvant Chemotherapy.

Authors:  Hui Ding; Xianhua Gui; Xubo Lin; Ruhua Chen; Tieliang Ma; Yunlu Sheng; Hourong Cai; Yan Fen
Journal:  Technol Cancer Res Treat       Date:  2016-09-29

5.  Breast Cancer 18F-ISO-1 Uptake as a Marker of Proliferation Status.

Authors:  Elizabeth S McDonald; Robert K Doot; Anthony J Young; Erin K Schubert; Julia Tchou; Daniel A Pryma; Michael D Farwell; Anupma Nayak; Amy Ziober; Michael D Feldman; Angela DeMichele; Amy S Clark; Payal D Shah; Hsiaoju Lee; Sean D Carlin; Robert H Mach; David A Mankoff
Journal:  J Nucl Med       Date:  2019-12-13       Impact factor: 10.057

Review 6.  The Molecular Function of σ Receptors: Past, Present, and Future.

Authors:  Hayden R Schmidt; Andrew C Kruse
Journal:  Trends Pharmacol Sci       Date:  2019-08-03       Impact factor: 14.819

7.  TM6SF2 and MAC30, new enzyme homologs in sterol metabolism and common metabolic disease.

Authors:  Luis Sanchez-Pulido; Chris P Ponting
Journal:  Front Genet       Date:  2014-12-11       Impact factor: 4.599

8.  A multiplatform approach identifies miR-152-3p as a common epigenetically regulated onco-suppressor in prostate cancer targeting TMEM97.

Authors:  Rui Henrique; Carmen Jerónimo; João Ramalho-Carvalho; Céline S Gonçalves; Inês Graça; David Bidarra; Eva Pereira-Silva; Sofia Salta; Maria Inês Godinho; Antonio Gomez; Manel Esteller; Bruno M Costa
Journal:  Clin Epigenetics       Date:  2018-03-27       Impact factor: 6.551

Review 9.  Small-Molecule Modulators of Sigma1 and Sigma2/TMEM97 in the Context of Cancer: Foundational Concepts and Emerging Themes.

Authors:  Halley M Oyer; Christina M Sanders; Felix J Kim
Journal:  Front Pharmacol       Date:  2019-10-21       Impact factor: 5.810

10.  Histatin-1 is an endogenous ligand of the sigma-2 receptor.

Authors:  Kyung-No Son; Hyun Lee; Dhara Shah; Sushma Kalmodia; Ryan Cree Miller; Marwan Ali; Arun Balasubramaniam; Stephanie M Cologna; Hyunjoon Kong; Deepak Shukla; Vinay Kumar Aakalu
Journal:  FEBS J       Date:  2021-07-23       Impact factor: 5.542

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.